ECO Animal Health sees stronger than expected demand in China and Asia

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has provided an update to its expected results for the year ended 31 March 2023. 

The ECO Group has experienced strong trading in its final quarter and it is clear that the demand for Aivlosin has been a little stronger than expected in China and Asia.  As a result, the Board now expects that Revenue and Earnings before Interest, Tax, Depreciation and Amortisation will be slightly ahead of market expectations for the current financial year. 

David Hallas, CEO, noted that “Our business has delivered good progress in key international markets especially Asia. We look forward to providing a further update following the completion of the financial year.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
ECO Animal Health Group plc

More articles like this

ECO Animal Health Group plc

Eco Animal Health delivering on earnings and R&D progress (VIDEO)

Eco Animal Health Group plc (LON:EAH) CEO David Hallas joins DirectorsTalk Interviews to discuss interim results for the six months ended 20th September. David talks us through the highlights, improved Chinese pork prices, excitement over new product developments, what

ECO Animal Health Group plc

ECO Animal Health Group appoint Haysmacintyre LLP as auditor

Following a competitive tender process overseen by the Group’s Audit & Risk Committee, ECO Animal Health Group (LON:EAH) has announced the resignation of BDO LLP as auditor and the appointment, with immediate effect, of Haysmacintyre LLP as auditor for the

ECO Animal Health Group plc

ECO Animal Health AGM to be held on 26 September 2022

ECO Animal Health Group plc (LON:EAH) has announced the publication of the following documents on the Company’s website: www.ecoanimalhealthgroupplc.com/investor-relations.aspx. ·     Annual Report and Accounts for the year ended 31 March 2022 ·    Notice of Annual General Meeting to be held

ECO Animal Health Group plc

ECO Animal Health delivers record China revenue in Q1

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has provided an update to its expected results for the year ended 31 March 2022.  The audit

ECO Animal Health Group plc

ECO Animal Health signs new bank facility agreement with NatWest

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that it has signed a new bank facility agreement with its bank, National Westminster Bank

ECO Animal Health Group plc

ECO Animal Health partners with Moredun Research Institute

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that its wholly owned subsidiary, ECO Animal Health Ltd, has entered into a research partnership

ECO Animal Health Group plc

ECO Animal Health Group pleased with recent trading

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets has provided an unaudited trading update for the financial year ending 31st March 2022. ECO commented in

ECO Animal Health Group plc

ECO Animal Health live investor presentation

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that Marc Loomes, CEO, Christopher Wilks, CFO, and Hafid Benchaoui, Global Head of R&D, will be

ECO Animal Health Group plc

ECO Animal Health appoint Tracey James as a Non-Executive Director

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health market, is pleased to announce the appointment of Tracey James as a Non-Executive Director with immediate effect. Tracey

No more posts to show